Jeffrey S Farrow's Net Worth
$13.5 Million
Who is Jeffrey S Farrow?
Jeffrey S Farrow has an estimated net worth of $13.5 Million. This is based on reported shares across multiple companies, which include RENOVIS INC, ZS Pharma, Inc., HYPERION THERAPEUTICS INC, Global Blood Therapeutics, Inc., and Tarsus Pharmaceuticals, Inc..
SEC CIK
Jeffrey S Farrow's CIK is 0001405253
Past Insider Trading and Trends
2018 was Jeffrey S Farrow's most active year for acquiring shares with 9 total transactions. Jeffrey S Farrow's most active month to acquire stocks was the month of January. 2022 was Jeffrey S Farrow's most active year for disposing of shares, totalling 28 transactions. Jeffrey S Farrow's most active month to dispose stocks was the month of July. 2022 saw Jeffrey S Farrow paying a total of $387,909.20 for 110,516 shares, this is the most they've acquired in one year. In 2015 Jeffrey S Farrow cashed out on 498,521 shares for a total of $13,451,345.80, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
RENOVIS INC No price found
V.P., Finance and CAO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -62.29K |
—
|
—
|
0
|
May 2
| |||
Form 4
| -7.41% | -4.99K |
$2.40 | -$11,968.80 | 62.29K |
Feb 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 31
| |||
Form 4
| +17.65% | 10K |
—
|
—
| 66.67K |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ZS Pharma, Inc. No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
HYPERION THERAPEUTICS INC No price found
CFO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -144.34K |
$46.00 | -$6,639,732.00 |
0
|
May 7
| |||
Form 4
| +511.23% | 120.78K |
$3.45 | $416,347.31 | 144.4K |
May 1
| |||
Form 4
| +320.00% | 18K |
—
|
—
| 23.63K |
Feb 9
| |||
Form 4
| -10.86% | -685.00 |
$24.28 | -$16,631.80 | 5.63K |
Jan 2
| |||
Form 4
|
∞
| 6.25K |
—
|
—
| 6.25K |
Mar 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Global Blood Therapeutics, Inc. No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -26.74K |
—
|
—
|
0
|
Oct 5
| |||
Form 4
| +766.46% | 23.65K |
$16.40 | $387,909.20 | 26.74K |
Sep 27
| |||
Form 4
| -90.18% | -28.36K |
$68.01 | -$2,266,450.75 | 3.09K |
Sep 1
| |||
Form 4
| +14.66% | 4.02K |
$32.40 | -$68,882.40 | 31.44K |
Aug 1
| |||
Form 4
| +5.57% | 1.45K |
$29.87 | -$39,279.05 | 27.42K |
Mar 1
| |||
Form 4
| +21.03% | 4.51K |
$29.33 | -$132,160.98 | 25.97K |
Feb 1
| |||
Form 4/A
| +30.29% | 4.67K |
$27.33 | -$118,994.82 | 20.07K |
Aug 1
| |||
Form 4
| +6.94% | 1.39K |
$29.85 | -$40,894.50 | 21.46K |
Sep 1
| |||
Form 4
| +30.29% | 4.67K |
$27.33 | -$118,994.82 | 20.07K |
Aug 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 4
| +67.70% | 6.22K |
$49.49 | -$290,258.85 | 15.4K |
Feb 1
| |||
Form 4
| +201.31% | 6.14K |
$67.48 | -$401,236.08 | 9.18K |
Aug 1
| |||
Form 4
| -83.30% | -15.21K |
$75.00 | -$1,140,600.00 | 3.05K |
Scheduled
|
Jul 13
| ||
Form 4
| -45.45% | -15.21K |
$67.00 | -$1,018,936.00 | 18.26K |
Scheduled
|
Jun 9
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
| +16.20% | 4.67K |
$65.26 | -$287,013.48 | 33.46K |
Feb 1 - Feb 3
| |||
Form 4
| +9.59% | 2.52K |
$76.88 | -$190,585.52 | 28.8K |
Dec 13
| |||
Form 4
| +27.33% | 5.64K |
$54.25 | -$185,589.25 | 26.28K |
Aug 1
| |||
Form 4
| +6.77% | 1.31K |
$58.51 | -$40,488.92 | 20.64K |
Apr 8
| |||
Form 4
| +24.26% | 3.77K |
$48.44 | -$104,824.16 | 19.33K |
Feb 1
| |||
Form 4
| +24.37% | 3.05K |
$16.40 | $49,987.20 | 15.55K |
Nov 27
| |||
Form 4
| +39.43% | 3.54K |
$43.15 | -$103,560.00 | 12.51K |
Aug 1
| |||
Form 4
| +17.07% | 1.31K |
$62.30 | -$43,111.60 | 8.97K |
Feb 14
| |||
Form 4
| +76.10% | 3.31K |
$58.93 | -$103,242.80 | 7.66K |
Jan 31 - Feb 1
| |||
Form 4
| +43.41% | 1.32K |
$58.15 | -$39,716.45 | 4.35K |
Jan 24
| |||
Form 4
| +58.77% | 1.12K |
$52.10 | -$45,691.70 | 3.03K |
Jan 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 11
| |||
Form 4
|
∞
| 1.91K |
$25.10 | -$28,890.10 | 1.91K |
Aug 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Tarsus Pharmaceuticals, Inc. (TARS) Snapshot price: $30.59
See Remarks
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +2,490.86% | 17.44K |
$27.47 | -$286,924.15 | 18.14K |
Jun 17 - Jun 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 7
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||